Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.54 |
| ▸ | JAK3 | P52333 | 6/20 | 0.54 |
| ▸ | ACVR1 | Q04771 | 9/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | BCR | P11274 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CCND3 | P30281 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5103295 | 0.94 | ACVR1 (0.54) | JAK2JAK3ACVR1ABL1BCR | |
| SCHEMBL5103237 | 0.90 | JAK2 (0.50) | JAK2JAK3ACVR1ABL1PDGFRB | |
| SCHEMBL5094669 | 0.89 | ACVR1 (0.57) | JAK2JAK3ACVR1ABL1PDGFRB | |
| SCHEMBL5103672 | 0.88 | CDK2 (0.52) | JAK2ACVR1SRCSYKCCNA2 | |
| SCHEMBL5090950 | 0.86 | ABL1 (0.57) | JAK2JAK3ACVR1ABL1BCR | |
| SCHEMBL5097244 | 0.85 | JAK2 (0.56) | JAK2JAK3ACVR1ABL1PDGFRB | |
| SCHEMBL5094850 | 0.85 | JAK2 (0.54) | JAK2JAK3ACVR1ABL1PDGFRB | |
| SCHEMBL5103291 | 0.84 | PIK3CA (0.49) | ACVR1ABL1BCRSRCCCNA2 | |
| SCHEMBL5090937 | 0.83 | ACVR1 (0.57) | JAK2JAK3ACVR1 | |
| SCHEMBL5096887 | 0.81 | AURKA (0.58) | JAK2JAK3ACVR1ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242667-A1 | Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases | SMITHKLINE BEECHAM CORPORATION | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242667-A1 | Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases | AURKA, AURKC, PLK1 | JAK2 205/4885JAK3 90/4885ACVR1 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.